# BioPorto signs global distribution agreement with Roche for NGAL test

BioPorto entered into a global distribution agreement with Roche to deliver an NGAL test for use on Roche's cobas c 501/c 502 analysers. Roche will have worldwide exclusive distribution rights.

- Type: Contract
- Announced: 2018-02-09
- Status: announced
- Products: NGAL test for acute kidney injury
- Sectors: [Medical Devices](https://endata.com/sectors/medical-devices.md)

## Companies

- [BioPorto](https://endata.com/companies/29984.md)
- [Roche Diagnostics](https://endata.com/companies/29985.md) (partner)

## Sources

- [globenewswire.com](https://www.globenewswire.com/news-release/2018/02/09/1338297/0/en/BioPorto-and-Roche-Diagnostics-sign-a-distribution-agreement-for-NGAL.html), 2018-02-09: "I am very happy to enter into a collaboration with Roche, who as a dominant player in the diagnostic space will ensure a broad global distribution of our NGAL test."

---
Data from Endata (https://endata.com/). Announcements are summarized from public sources and may be incomplete; check the linked originals.